Payment overview · 2025
General Payments
$668.62
17 reported records · 5 companies
Healthcare provider profile · identity verified
Shashi Madan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSON, GA · NPI 1740359629
Verified facts
What the public records show
CMS Open Payments records show Shashi Madan, MD received $668.62 in general payments during 2025 across 17 reported records.
AstraZeneca Pharmaceuticals LP accounted for 67.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $448.06 | 67.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $144.16 | 21.6% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.34 | 4.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.75 | 3.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.31 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $668.62 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $250.06 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $198.00 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $144.16 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.34 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.34 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.75 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 460 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 392 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 359 | 114 |
| Metformin Hcl | Metformin Hcl | 256 | 80 |
| Lisinopril | Lisinopril | 208 | 57 |
| Gabapentin | Gabapentin | 205 | 62 |
| Omeprazole | Omeprazole | 197 | 60 |
| Losartan Potassium | Losartan Potassium | 173 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 172 | 49 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 159 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 43 |
| Prednisone | Prednisone | 142 | 80 |
| Tramadol Hcl | Tramadol Hcl | 141 | 52 |
| Meloxicam | Meloxicam | 137 | 40 |
| Metformin Hcl Er | Metformin Hcl | 137 | 43 |
| Trazodone Hcl | Trazodone Hcl | 137 | 40 |
| Amoxicillin | Amoxicillin | 135 | 105 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 52 |
| Clonidine Hcl | Clonidine Hcl | 114 | 32 |
| Famotidine | Famotidine | 114 | 49 |
| Allopurinol | Allopurinol | 108 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 34 |
| Simvastatin | Simvastatin | 99 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 97 | 33 |
| Azithromycin | Azithromycin | 95 | 76 |
| Fenofibrate | Fenofibrate Nanocrystallized | 95 | 29 |
| Furosemide | Furosemide | 93 | 31 |
| Lovastatin | Lovastatin | 92 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 92 | 36 |
| Sertraline Hcl | Sertraline Hcl | 89 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 25 |
| Januvia | Sitagliptin Phosphate | 83 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 41 |
| Metoprolol Succinate | Metoprolol Succinate | 80 | 28 |
| Alprazolam | Alprazolam | 79 | 26 |
| Carvedilol | Carvedilol | 76 | 23 |
| Glimepiride | Glimepiride | 76 | 20 |
| Cephalexin | Cephalexin | 70 | 50 |
| Clopidogrel | Clopidogrel Bisulfate | 70 | 22 |
| Montelukast Sodium | Montelukast Sodium | 66 | 15 |
| Celecoxib | Celecoxib | 64 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 25 |
| Glipizide Er | Glipizide | 62 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 62 | 51 |
| Benazepril Hcl | Benazepril Hcl | 61 | 18 |
| Farxiga | Dapagliflozin Propanediol | 61 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | 16 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Jardiance | Empagliflozin | 54 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 53 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 13 |
| Methylprednisolone | Methylprednisolone | 51 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 51 | 14 |
| Atenolol | Atenolol | 50 | 13 |
| Eliquis | Apixaban | 47 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 12 |
| Potassium Chloride | Potassium Chloride | 46 | 18 |
| Ozempic | Semaglutide | 45 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 24 |
| Donepezil Hcl | Donepezil Hcl | 43 | 16 |
| Ezetimibe | Ezetimibe | 43 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 42 | 13 |
| Meclizine Hcl | Meclizine Hcl | 41 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 34 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 22 |
| Lorazepam | Lorazepam | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 12 |
| Telmisartan | Telmisartan | 34 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | 16 |
| Colesevelam Hcl | Colesevelam Hcl | 29 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 11 |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | 20 |
| Rybelsus | Semaglutide | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | 13 |
| Colchicine | Colchicine | 25 | 11 |
| Spironolactone | Spironolactone | 25 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Vascepa | Icosapent Ethyl | 23 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 18 |
| Sucralfate | Sucralfate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 11 |
| Valsartan | Valsartan | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $668.62 · 17 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, Kerendia, OTEZLA, REPATHA, REXULTI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Rexulti play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error